Drugs & Targets FDA grants Enhertu Breakthrough Therapy designation as post-neoadjuvant therapy for HER2+ early breast cancer January 09, 2026Vol.52 No.1
Drugs & Targets China NMPA approves Pimicotinib as systemic treatment in tenosynovial giant cell tumor January 09, 2026Vol.52 No.1
Drugs & Targets Niowave expands global agreement with AstraZeneca for 10-year actinium-225 supply January 09, 2026Vol.52 No.1
Drugs & Targets Kallisio partners with Stanford Health Care on rollout of Stentra system for head-and-neck radiation therapy January 09, 2026Vol.52 No.1
Drugs & Targets SOPHiA GENETICS partners with MD Anderson on AI-driven precision oncology January 09, 2026Vol.52 No.1
Drugs & Targets FDA grants regular approval to rucaparib for metastatic castration-resistant prostate cancer December 19, 2025Vol.51 No.46
Drugs & Targets FDA and OS Therapies hold Type C meeting regarding phase IIb clinical trial of OST-HER2 in the prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma December 19, 2025Vol.51 No.46
Drugs & Targets FDA awards National Priority Voucher to Tecvayli+Darzalex based on phase III study results December 19, 2025Vol.51 No.46
Drugs & Targets EC approval of Minjuvi in relapsed or refractory follicular lymphoma December 19, 2025Vol.51 No.46
